Stockscreener 앱 받기
54.94
1.84%
0.99
Hemab Therapeutics Holdings Inc 주식(COAG)의 최신 뉴스
Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics - Stock Titan
Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake - Stock Titan
HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics - MarketBeat
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64 - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership - Stock Titan
Hemab Therapeutics stock price target raised to $60 by H.C. Wainwright - Investing.com Canada
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
FMR LLC Acquires Stake in Hemab Therapeutics Holdings Inc (COAG) - GuruFocus
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Hemab Therapeutics Reports Q2 2026 Financials and Pipeline Progress in Latest 10-Q Filing - Kalkine Media
Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Hemab Therapeutics Gains FDA Backing to Advance Sutacimig Into Phase 3 Trial for Glanzmann Thrombasthenia - Minichart
Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com - Investing.com Nigeria
Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Hemab Therapeutics reports Q2 2026 net loss of $24.2M, cash runway into 2029 after $317M IPO proceeds - TradingView
Hemab Unveils Peptide-Based Approach to Heavy Menstrual Bleeding - Stock Titan
COAG Stock Price and Chart — NASDAQ:COAG - TradingView
Hemab Therapeutics (NASDAQ: COAG) investors detail 5.1% passive ownership stake - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Hits New 1-Year HighTime to Buy? - MarketBeat
FMR LLC reports 7.9% Hemab Therapeutics (COAG) stake on Schedule 13G - Stock Titan
Sofinnova group (NASDAQ: COAG) discloses 5.4% Hemab Therapeutics ownership on Schedule 13G - Stock Titan
Hemab Therapeutics (NASDAQ:COAG) Trading Down 4.8%What's Next? - MarketBeat
Hemab Therapeutics Holdings Ord Shs (Proposed) - TradingKey
Hemab Therapeutics Holdings, Inc. Revenue Breakdown – NASDAQ:COAG - TradingView
Ra Capital Nexus Fund Iv, L.p. Net Worth (2026) - GuruFocus
Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA) - Seeking Alpha
Mads Nikolaj Behrndt Eriksen Net Worth (2026) - GuruFocus
Biotech IPO gains crush numerous AI listings - PressReader
Biotech IPO gains crush AI listings with standout 55% return - The Edge Singapore
Ananthram Sreenivasa Murthy Net Worth (2026) - GuruFocus
SpaceX Stock Closes At Fresh Low After Seven Straight Days Of Losses - Yahoo Finance
Ai Den Mab Llc Net Worth (2026) - GuruFocus
The Robot Maker's Paradox - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Hits New 12-Month HighWhat's Next? - MarketBeat
Culpeo Minerals expands Chile landholding by 45% with new licences - Yahoo Finance
After Plunging 32.2% in 4 Weeks, Here's Why the Trend Might Reverse for D-WAVE QUANTUM (QBTS) - Yahoo Finance
Insight Global Opens New Seattle Hub to Support Next Phase of Growth Across the Pacific Northwest - Yahoo Finance
DiamondRock Hospitality Company (DRH) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
IREN stock jumps as AI cloud contract wins lift annual revenue target - Yahoo Finance
Why this venture capitalist is bullish on Anthropic's IPO — not OpenAI's - Yahoo Finance
Plug Power vs. FuelCell: Both Are Hot in 2026, but Only One Is Worth Buying Now - Yahoo Finance
QScreen AI Deepens US Institutional Pipeline as Screening Platform Adds Escalation-Based Review Capability - Yahoo Finance
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Why Is Lucid (LCID) Stock Rocketing Higher Today - Yahoo Finance
Sellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial Result - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5%Here's What Happened - MarketBeat
WESTSHORE TERMINALS ANNOUNCES AGREEMENT RENEWAL WITH EVR OPERATIONS LIMITED - Yahoo Finance
Cracker Barrel (CBRL): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Wall Street traders can soon pay for early looks at Truth Social posts - Yahoo Finance
Hemab Therapeutics Holdings, Inc. Common Stock (NASDAQ: COAG) Stock Price, News & Analysis - Kalkine
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Trading Down 3.8%Should You Sell? - MarketBeat
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Yahoo Finance
FY2027 Earnings Estimate for COAG Issued By HC Wainwright - MarketBeat
Hemab Therapeutics' Sutacimig Continues to Support Durable Bleed Reduction, Wedbush Says - Moomoo
Why Is ASML Stock Jumping Over 5% Premarket Today? - Yahoo Finance
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Analysts Are Bullish on Top NA Stocks: HawkEye 360, Inc. (HAWK), SpaceX (SPCX) - The Globe and Mail
Hemab Therapeutics reports positive Phase 2 sutacimig data - grafa.com
Corning Earnings Preview: What to Expect - Yahoo Finance
Hemab Therapeutics: Strong HMB-002 Data Drive Higher Probability of Success and Lift Price Target from $36 to $46 with Buy Rating - TipRanks
Hemab Advances Bleeding Disorder Pipeline - Sahm
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress - The Manila Times
Hemab Therapeutics Presents Sustained Sutacimig Bleed Reduction Data and Preclinical Factor VII Deficiency Results at ISTH 2026 - Quiver Quantitative
Hemab GT study finds 72% of patients 40+ still bleed weekly - Stock Titan
Hemab Therapeutics (COAG) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
0.52%
0.07%
자본화:
|
볼륨(24시간):